Patients with favorable (fav)-risk AML, including AML due to genetic abnormalities of RUNX1-RUNX1T1, CBFB-MYH11 or biallelic mutated CEBPA (CEBPAbi+), may benefit from allo-HSCT during CR1, as it is a risk-directed, MRD-based therapy. This evidence concerns the gene RUNX1T1 and acute myeloid leukemia.